Acute Schizophrenia (DBCOND0031645)

Identifiers

Synonyms

Acute schizophrenia / Schizophrenia NOS / Schizophrenic disorders / Dementia praecox / Schizophrenia, unspecified / Unspecified schizophrenia / Unspecified schizophrenia, unspecified state / Schizophrenia

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Amisulpride	A dopamine D2 receptor antagonist used in the treatment of acute and chronic schizophrenia, and in the prevention and treatment of postoperative nausea and vomiting in adults.	D(2) dopamine receptortarget D(3) dopamine receptortarget 5-hydroxytryptamine receptor 7target 5-hydroxytryptamine receptor 2Atarget Erythrocytecarrier Multidrug and toxin extrusion protein 1transporter Multidrug and toxin extrusion protein 2transporter ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Solute carrier family 22 member 1transporter Mu-type opioid receptortarget Delta-type opioid receptortarget Kappa-type opioid receptortarget
Sulpiride	A selective D2 dopamine receptor antagonist indicated to treat chronic and acute schizophrenia.	D(2) dopamine receptortarget D(3) dopamine receptortarget Cholinesteraseenzyme Carbonic anhydrase 2target Carbonic anhydrase 3target Albumincarrier Solute carrier family 22 member 1transporter Solute carrier family 22 member 2transporter Multidrug and toxin extrusion protein 1transporter Multidrug and toxin extrusion protein 2transporter D(4) dopamine receptortarget Solute carrier family 22 member 3transporter ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter
Zuclopenthixol	An antipsychotic indicated for the management of schizophrenia. The acuphase formulation is indicated for initial treatment of acute psychosis or exacerbation of psychosis, while the depot formulation is best for maintenance.	D(1A) dopamine receptortarget D(1B) dopamine receptortarget D(2) dopamine receptortarget Cytochrome P450 2D6enzyme Alpha-1A adrenergic receptortarget Alpha-2A adrenergic receptortarget 5-hydroxytryptamine receptor 2Atarget Histamine H1 receptortarget Cytochrome P450 3A4enzyme

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05325645	Trial of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Schizophrenia	Brexpiprazole	treatment	3	recruiting
NCT06589817	A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute Schizophrenia	Aripiprazole	treatment	3	not_yet_recruiting
NCT03160521	Study to Evaluate the Efficacy and Safety of Risperidone in Situ Microparticle (ISM)® in Patients With Acute Schizophrenia	Risperidone	treatment	3	completed
NCT00140166	Treatment of Acute Schizophrenia With Vitamin Therapy	Ascorbic acid Nicotinamide Pyridoxine	treatment	4	completed
NCT01396421	Study of the Effectiveness of Three Different Doses of OPC-34712 in the Treatment of Adults With Acute Schizophrenia	Brexpiprazole	treatment	3	completed
NCT01668797	Efficacy, Safety, and Tolerability of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults With Schizophrenia	Brexpiprazole	treatment	3	completed
NCT00838032	Pilot Study to Evaluate the Efficacy and Safety of Quetiapine Fumarate Instant-Release (Seroquel IR) in Controlling Agitation and Aggressive Symptoms in the Acute Treatment of Patients With Schizophrenia	Haloperidol Quetiapine	treatment	4	unknown_status
NCT01393613	Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia	Brexpiprazole	treatment	3	completed
NCT01490086	RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder	Aripiprazole Brilaroxazine	treatment	2	completed
NCT00350467	A Randomized, Active-controlled, Double-blind, Parallel-Goup Study of the Efficacy and Safety of Extended Release(ER) Paliperidone in the Treatment of Schizophrenia	Olanzapine Paliperidone	treatment	3	completed